Document Detail


Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions.
MedLine Citation:
PMID:  21978965     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Implantable cardioverter-defibrillators (ICDs) remain the treatment of choice for the prevention of life-threatening arrhythmias. However, many patients with ICDs require additional antiarrhythmic therapy to reduce the morbidity associated with recurrent arrhythmia-triggered ICD interventions.
OBJECTIVE: Our study aimed to evaluate the safety and efficacy of celivarone in reducing these interventions.
METHODS: A total of 153 eligible ICD recipients were randomized to receive either placebo or celivarone 100 or 300 mg once daily for 6 months. The primary end point was the prevention of arrhythmia-triggered ICD therapies.
RESULTS: Fewer ventricular tachycardia and ventricular fibrillation episodes were observed in the 300-mg celivarone group than in the placebo group, with a relative risk reduction of 46%, which was not statistically significant. The analysis of all-cause shocks showed a trend toward a decreased number of events in the celivarone 300-mg group. A post hoc analysis of the primary end point in a subgroup of patients in the celivarone 300-mg group, who had received ICD therapy within 1 month of randomization, showed a significant benefit (P = .032). Celivarone was not associated with an increased risk of torsades de pointes, thyroid dysfunction, or pulmonary events. More heart failure events were reported in the celivarone groups than in the placebo group, but the difference was not statistically significant.
CONCLUSION: Celivarone tends to reduce ventricular tachycardia-/ventricular fibrillation-triggered ICD therapies. This effect was not statistically significant. There was a trend toward greater efficacy in the 300-mg group, especially in patients undergoing ICD therapy within 30 days prior to randomization. Overall, celivarone was well tolerated.
Authors:
Olivera Gojkovic; Etienne M Aliot; Alessandro Capucci; Stuart J Connolly; Harry Crijns; Stefan H Hohnloser; Piotr Kulakowski; Denis Roy; David Radzik; Bramah N Singh; Peter R Kowey
Related Documents :
12892235 - Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gl...
17760715 - Eradication of helicobacter pylori does not reduce the incidence of gastroduodenal ulce...
21751165 - Lithium carbonate pre-treatment in 131-i therapy of hyperthyroidism.
21626525 - Limited use of interleukin 28b in the setting of response-guided treatment with detaile...
9400765 - Laser photocoagulation for retinal detachments and retinal tears in cytomegalovirus ret...
22561385 - Blind or ultrasound-guided corticosteroid injections and short-term response in subacro...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2011-10-04
Journal Detail:
Title:  Heart rhythm : the official journal of the Heart Rhythm Society     Volume:  9     ISSN:  1556-3871     ISO Abbreviation:  Heart Rhythm     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-27     Completed Date:  2013-01-11     Revised Date:  2014-01-30    
Medline Journal Info:
Nlm Unique ID:  101200317     Medline TA:  Heart Rhythm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  217-224.e2     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anti-Arrhythmia Agents / adverse effects,  therapeutic use*
Arrhythmias, Cardiac / drug therapy,  etiology,  prevention & control*
Benzofurans / adverse effects,  therapeutic use*
Defibrillators, Implantable
Double-Blind Method
Female
Follow-Up Studies
Heart Ventricles / pathology
Humans
Male
Middle Aged
Tachycardia, Ventricular / etiology,  prevention & control*
Ventricular Fibrillation / etiology,  prevention & control*
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Benzofurans; K45001587E/celivarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of inflammation on heart rate and rhythm in a canine model of cardiac surgery.
Next Document:  Prospective Comparison of Discrimination Algorithms to Prevent Inappropriate ICD Therapy: Primary Re...